Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Diseases
Events Partner Content 3rd Chronic Kidney Disease Drug Development (CKD3) Summit Advance Therapeutics for Chronic Kidney Disease
News Otsuka has high hopes for its 'drug creation engine' acquisi... Otsuka is paying $430 million for a US clinical-stage biotech company it hopes will act as a ‘drug creation engine’ to accelerate its research into kidney diseases.
News Summit climbs on rumour of $15bn AstraZeneca interest Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face